Another step toward the cure of metastatic renal cell carcinoma?

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5017-5019

  Vogelzang, Nicholas J ^a,b  

^a Department of Hematology Oncology   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; EVEROLIMUS; GEMCITABINE; INTERFERON; PAZOPANIB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; KIDNEY NEOPLASMS; OXONIC ACID; TEGAFUR;

EID: 79951935241     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5044     Document Type: Editorial

References (35)

1. Vogelzang NJ: Treatment options in metastatic renal carcinoma: An embarrassment of riches. J Clin Oncol 24:1-3, 2006
2. Naito S, Eto M, Shinohara N, et al: Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 28:5022-5029, 2010
3. Samlowski WE, Wong B, Vogelzang NJ: Management of renal cancer in the tyrosine kinase inhibitor era: A view from 3 years on. BJU Int 102:162-165, 2008 (Pubitemid 351852600)
4. Rini BI: New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16:1348-1354, 2010
5. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004 (Pubitemid 41079774)
6. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
7. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
8. Huang D, Ding Y, Zhou M, et al: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071, 2010
9. Daliani DD, Tannir NM, Papandreou CN, et al: Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104:456-460, 2009
10. Cho DC, Puzanov I, Regan MM, et al: Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 32:181-185, 2009
11. Cook KM, Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 60:222-243, 2010
12. Einhorn LH, Williams SD, Chamness A, et al: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340-348, 2007 (Pubitemid 47124134)
13. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
14. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20:303-321, 1993 (Pubitemid 23154480)
15. Stadler W: Chemotherapy and other approaches in the management of metastatic renal cell carcinoma, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology, 3rd Edition. Philadelphia, PA, Lippincott Williams & Wilkins, 2005
16. Samuels BL, Hollis DR, Rosner GL, et al: Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A cancer and leukemia group B study. Clin Cancer Res 3:1977-1984, 1997
17. Huang H, Menefee M, Edgerly M, et al: A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1634-1641, 2010
18. Rini BI, Vogelzang NJ, Dumas MC, et al: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419-2426, 2000 (Pubitemid 30415829)
19. Chung EK, Posadas EM, Kasza K, et al: A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol [epub ahead of print on April 14, 2010]
20. Tannir NM, Thall PF, Ng CS, et al: A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180:867-872, 2008
21. Waters JS, Moss C, Pyle L, et al: Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 91:1763-1768, 2004 (Pubitemid 39664962)
22. Stadler WM, Halabi S, Rini B, et al: A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 107:1273-1279, 2006 (Pubitemid 44452776)
23. Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al: A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group study S0312. Am J Clin Oncol [epub ahead of print on May 29, 2009]
24. Bellmunt J, Trigo JM, Calvo E, et al: Activity of a multitargeted chemoswitch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06). Lancet Oncol 11:350-357, 2010
25. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289, 2009
26. Wenzel C, Locker GJ, Schmidinger M, et al: Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 39:48-54, 2002 (Pubitemid 34062495)
27. Petrioli R, Paolelli L, Francini E, et al: Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anticancer Drugs 18:817-820, 2007 (Pubitemid 46975968)
28. Pagliaro LC, Perez CA, Tu SM, et al: Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol 24:487-491, 2006 (Pubitemid 44810012)
29. Naito S, Yamamoto N, Takayama T, et al: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients. Eur Urol 57:317-325, 2010
30. Canil C, Hotte S, Mayhew LA, et al: Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: A systematic review. Can Urol Assoc J 4:201-208, 2010
31. Righi L, Papotti MG, Ceppi P, et al: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28:1534-1539, 2010
32. Mizutani Y, Wada H, Yoshida O, et al: Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 9:1453-1460, 2003 (Pubitemid 36418401)
33. Colavito D, Cartei G, Dal Bianco M, et al: Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. Cancer Chemother Pharmacol 64:1195-1200, 2009
34. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
35. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)